Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
Strumberg
D
D
Department of Hematology and Oncology, University of Bochum, Marienhospital Herne, Herne, Germany. dirk.strumberg@marienhospital-herne.de
Schultheis
B
B
Scheulen
M E
ME
Hilger
R A
RA
Krauss
J
J
Marschner
N
N
Lordick
F
F
Bach
F
F
Reuter
D
D
Edler
L
L
Mross
K
K
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C501466:nimotuzumab; D066246:ErbB Receptors